Results of the Annual General Meeting held on April 26, 2011

DUBLIN, April 26, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ: SHPGY), the global specialty biopharmaceutical company (the "Company") announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

                                  For*           Against         Withheld**
    1.  To receive the     434,920,990 99.46%  2,344,010  0.54%   1,047,773
        Company's accounts
        together with the
        Directors' and
        Auditors' reports
    2.  To approve the     371,352,068 85.39% 63,551,261 14.61%   3,409,444
        Directors'
        remuneration
        report
    3.  To re-elect        417,978,353 95.95% 17,628,440  4.05%   2,705,980
        Matthew Emmens as
        a Director of the
        Company
    4.  To re-elect Angus  435,218,771 99.61%  1,698,734  0.39%   1,395,268
        Russell as a
        Director of the
        Company
    5.  To re-elect Graham 435,152,221 99.60%  1,764,913  0.40%   1,395,639
        Hetherington as a
        Director of the
        Company
    6.  To re-elect David  436,960,582 99.92%    358,052  0.08%     994,139
        Kappler as a
        Director of the
        Company
    7.  To re-elect        435,708,499 99.63%  1,614,018  0.37%     990,256
        Patrick Langlois
        as a Director of
        the Company
    8.  To re-elect Dr     434,370,246 99.37%  2,740,035  0.63%   1,202,492
        Jeffrey Leiden as
        a Director of the
        Company
    9.  To elect Dr David  436,960,853 99.92%    353,430  0.08%     998,490
        Ginsburg as a
        Director of the
        Company
    10. To elect Anne      436,387,198 99.79%    930,666  0.21%     994,909
        Minto as a
        Director of the
        Company
    11. To re-appoint      436,552,369 99.82%    773,722  0.18%     986,682
        Deloitte LLP as
        Auditors of the
        Company
    12. To authorize the   436,986,474 99.97%    139,910  0.03%   1,186,389
        Audit, Compliance
        & Risk Committee
        to determine the
        remuneration of
        the Auditors
    13. To authorize the   389,393,127 90.24% 42,136,878  9.76%   6,782,768
        allotment of
        shares
    14. To authorize the   436,331,828 99.81%    812,978  0.19%   1,167,967
        disapplication of
        pre-emption rights
    15. To authorize       435,373,076 99.58%  1,834,752  0.42%   1,104,945
        market purchases
    16. To adopt new       434,712,537 99.84%    702,963  0.16%   2,897,273
        Articles of
        Association
    17. To approve the     378,440,959 86.57% 58,704,213 13.43%   1,167,601
        notice of period
        for general
        meetings

    * These figures include discretionary votes

** A vote "withheld" is not a vote in law and is not counted in the calculation of the votes "for" or "against" a resolution.

As at the record date, April 24, 2011, there were 562,246,293 ordinary shares in issue. Shareholders are entitled to one vote per share.

In accordance with Listing Rule 9.6.2 copies of the resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: http://www.hemscott/nsm.do.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

    For further information please contact:

    Investor         Eric Rojas ([email protected])            +1-781-482-0999
    Relations
                     Sarah Elton-Farr ([email protected])  +44-1256-894157
    Media            Jessica Mann ([email protected])          +44-1256-894-280

SOURCE Shire plc